SCHEMBL2173360

SCHEMBL2173360

NS(=O)(=O)c1cc2cccc(OCc3ccccc3)c2s1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 10/20 0.64
CA1 P00915 4/20 0.44
CA9 Q16790 4/20 0.44
CA12 O43570 3/20 0.44
CA7 P43166 2/20 0.44
CA4 P22748 1/20 0.43
CA5A P35218 1/20 0.43
CA5B Q9Y2D0 1/20 0.43
MAPT P10636 2/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
MAPK1 P28482 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
IKBKB O14920 2/20 0.41
F9 P00740 1/20 0.41
F10 P00742 1/20 0.41
MRGPRX4 Q96LA9 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
SRD5A2 P31213 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2175456 0.87 CA2 (0.47) CA2MAPTL3MBTL1MAPK1TDP1
SCHEMBL2175949 0.79 CA2 (0.72) CA2
SCHEMBL2173848 0.79 CA2 (1.00) CA2CA1CA9CA12
SCHEMBL10373938 0.78 CA2 (0.67) CA2NPC1RAB9A
SCHEMBL10368819 0.76 CA2 (0.60) CA2MAPK1
SCHEMBL10371319 0.74 CA2 (0.64) CA2SMN1; SMN2
SCHEMBL27254502 0.72 HPGD (0.48) MAPTL3MBTL1MAPK1TDP1MRGPRX4
SCHEMBL1013565 0.70 CA1 (0.56) CA2CA1CA9CA12CA7
SCHEMBL10367795 0.70 CA2 (1.00) CA2CA1CA9CA12
SCHEMBL10370673 0.70 CA2 (0.52) CA2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7973051-B2 Aminothiazoles as FBPase inhibitors for diabetes HOFFMAN-LA ROCHE INC. (US) 2011-07-05 US disclosed
EP-2227468-A1 AMINOTHIAZOLE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2010-09-15 EP disclosed
US-20090143448-A1 NEW AMINOTHIAZOLES AS FBPASE INHIBITORS FOR DIABETES F. HOFFMANN-LA ROCHE AG (CH) 2009-06-04 US disclosed
WO-2009068467-A1 AMINOTHIAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-06-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143448-A1 NEW AMINOTHIAZOLES AS FBPASE INHIBITORS FOR DIABETES FBP1, SLC5A1, DPP4 CA2 1616/4885CA1 3718/4885CA9 2185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.